What Actually Happens When You Stop Taking a GLP-1
Trial data on stopping semaglutide shows most of the lost weight comes back within a year. Here is what the STEP 1 extension found.
The question people ask far less often than "does it work" is "what happens after." As millions of prescriptions for semaglutide and tirzepatide have gone out, the more uncomfortable data point sitting underneath the headlines is what the body does once the injections stop.
There is now a clear trial-based answer, and it is not the one the marketing implies. Weight tends to come back.
What the STEP 1 extension actually studied
The original STEP 1 trial ran 1,961 adults with overweight or obesity, without diabetes, through 68 weeks of once-weekly semaglutide 2.4 mg or placebo alongside lifestyle counseling, and it is the trial that underpinned Wegovy's approval. But a subset of participants who completed the full 68 weeks were then followed for an additional year off treatment, in what researchers called the STEP 1 trial extension.
Published results, summarized in the peer-reviewed extension paper and reported by the University of Liverpool, found that participants had lost a mean of 17.3 percent of body weight on semaglutide by week 68, compared with 2.0 percent on placebo. After treatment and lifestyle support were both withdrawn at week 68, the semaglutide group regained 11.6 percentage points of that lost weight by week 120, one year later.
The net result a year after stopping
Do the arithmetic and the picture is stark: participants ended up a net 5.6 percent below their original starting weight at the one-year, off-drug mark, having lost 17.3 percent at peak. In plain terms, most of the weight lost during 68 weeks of treatment came back within twelve months of stopping.
It is worth being precise about what this trial did and did not test. Participants were withdrawn from both the drug and the structured lifestyle counseling at the same time, at week 68, so the extension measures the combined effect of stopping medication and stopping intensive behavioral support together, not medication withdrawal in isolation. A person who kept working with a dietitian or trainer after stopping the drug was not the population this specific dataset captured.
Why this happens biologically
This is not simply a willpower story. GLP-1 receptor agonists work by suppressing appetite signaling in the brain and slowing gastric emptying. Remove the drug and those appetite-dampening effects fade, while the body's own hunger and metabolic adaptation systems, which tend to push back against weight loss regardless of how it was achieved, are still active. Researchers increasingly describe obesity treatment with these drugs as something closer to managing a chronic condition than completing a course of treatment, similar in structure to blood pressure medication rather than a course of antibiotics.
That framing has practical consequences for how these drugs get prescribed and paid for. If the expected pattern is that benefits fade within about a year of stopping, then insurers, health systems and patients are really weighing the cost and commitment of years of continuous treatment, not a single course with a lasting endpoint, a distinction that changes the entire calculation of whether starting the drug makes sense for a given person's goals and budget.
Cardiometabolic markers regress too
The STEP 1 extension also tracked more than weight. Improvements in blood pressure, cholesterol, and blood sugar markers seen during the treatment period moved back toward baseline once semaglutide was stopped, tracking the weight regain rather than persisting independently of it, a pattern also indexed in the trial's own listing in Diabetes, Obesity and Metabolism.
What this means for how the drugs get used
The clinical implication researchers have drawn from this data is that these medicines were not designed, and have not been shown, to work as a short course that produces a permanent change. Separate real-world claims data referenced by Epic Research suggests outcomes outside of a controlled trial vary person to person, but the controlled STEP 1 extension remains the most rigorous look at what discontinuation does on average.
None of this means the drugs do not work. It means the honest framing is closer to ongoing management than a cure, a distinction that matters both for what patients should expect and for how insurers and health systems think about covering years, not months, of treatment.
This article reports on published trial data and is not medical advice. Decisions about starting, continuing, tapering or stopping any GLP-1 receptor agonist should be made with a clinician who can weigh a patient's specific health history and goals, not on the basis of a single study's average result.
As more people reach the multi-year mark on these drugs, longer-term data on what sustained use looks like, and what happens when people eventually do stop for medical or financial reasons, will matter more than the initial weight loss numbers ever did.
Published in The Outspoken Digest
Read Next
More Health →
